knowledge -WSS

knowledge

author：comprehensive 2025-09-28 01:16:51 - browse：6569

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： WuXi Biologics beefs up its lobbying operation

entertainment

WSS

Cherokee Nation medical school graduates its first class

Fertility clinic egg and embryo storage is a disaster

Ripples from Flovent's discontinuation is killing children with asthma

UnitedHealth’s Optum accused of antitrust violations in California

BIO selects John Crowley as new CEO

Fetal surgery at risk from Dobbs and new abortion restrictions

entertainment

knowledge

focus

Activists slam private health insurers over coverage restrictions

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Hollywood unions extend contract negotiations for actors

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

In age of alternative facts, a scholarly course on calling out crap

Ripples from Flovent's discontinuation is killing children with asthma

Malaria cases in Florida and Texas: Here’s what you need to know

Despite FDA concern, risk that CAR

Virginia high school admissions case could be legal follow

What don’t we know about an Alzheimer’s drug side effect?

Wikipedia

Free medical tuition alone isn't enough to close gaps in primary care

What don’t we know about an Alzheimer’s drug side effect?

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

STAT reporters are Pulitzer Prize finalists for investigative reporting

CVS is willing to dump 10% of its Medicare Advantage members

WuXi Biologics execs register to lobby as Congress comes for the company

focus

entertainment

entertainment

focus